RHEINFELDEN, Switzerland, 20.05.2021 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, today announced entering new markets in Belgium, the Netherlands and Luxembourg (“Benelux”). The development of these markets underlines Tillotts’ commitment in accelerating its expansion in Europe and is expected to continue fuelling strong growth for the group in 2021. In November 2020, Tillotts acquired DIFICLIR™, a drug for the treatment of Clostridioides difficile infections (CDI), taking the next important step in opening new affiliates in Europe.
The new structure will allow the company to fully exploit its potential by offering innovative pharmaceutical products in the field of gastroenterology and beyond. Given the geographical proximity, the Benelux organisation will be managed by Tillotts Pharma France, which relies on strong expertise within the gastrointestinal therapeutic area working closely together with scientific experts, medical and patients’ organisations.
By being present in the top five EU markets, Tillotts continues to pursue its goal of building a strong commercial structure with group affiliates in strategic markets. With more than 30 million inhabitants, the Benelux region is offering substantial growth opportunities. Edouard Bieth, Managing Director Tillotts Pharma France, says: “Benelux represents the 6th biggest pharma market in Europe, emphasising the necessity of being present in this region. Taking this important step now reflects our ambition to become a leader in gastroenterology”.
With the latest acquisition of DIFICLIR™, which will drive sustainable growth for the group, the company stresses its strategic course in further developing towards an innovative and balanced product portfolio. Benelux started the distribution of DIFICLIR™ early in April 2021. In addition to successfully integrating DIFICLIR™ within Europe and offering patients with CDI a first-line treatment option, Tillotts will also continue to lay great importance and focus on IBD, where demand continues to grow, as well as other specialty therapeutics. The company will strengthen its customer-oriented culture as a fast-moving specialty pharmaceutical company bringing unique expertise to all stakeholders involved in GI diseases. “We aim at a strong presence and performance in all key markets and become the preferred partner in GI,” says Mattias Norrman, Chief Operations Officer at Tillotts, “By working closely with healthcare professionals to provide better healthcare solutions, Tillotts will help to enhance the outcome for millions of people with gastrointestinal diseases.”
For more information, please contact:
Tillotts Pharma AG
Senior Manager Corporate Communications
Phone: +41 61 935 2759
Tillotts Pharma France S.A.S.
Phone: +33 (0) 1 55 07 97 40
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and C.Difficile infection in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.
For more information, please visit www.tillotts.com
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp
Download high-resolution photos here https://www.tillotts.com/about-us/visuals/